CTS 1027

Drug Profile

CTS 1027

Alternative Names: CTS-1027

Latest Information Update: 25 Jul 2014

Price : $50

At a glance

  • Originator Roche
  • Developer Conatus Pharmaceuticals
  • Class Hepatoprotectants; Small molecules
  • Mechanism of Action Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Liver disorders

Most Recent Events

  • 25 Jul 2014 Discontinued - Phase-II for Liver disorders in Puerto Rico (PO)
  • 25 Jul 2014 Discontinued - Phase-II for Liver disorders in USA (PO)
  • 31 Mar 2012 CTS 1027 is no longer licensed to Conatus Pharmaceuticals (Conatus Pharmaceuticals' 2013 Form 10-K filed in March 2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top